महावीर जयंती की हार्दिक शुभकामनाये #HappyMahavirJayanti

#happylabourday2023

We welcome delegates from the top 20 economies to join us to G20's Health Working Group with Department of Pharmaceuticals 🇮🇳, Ministry of Health at HICC, Hyderabad to know India's global collaboration in R&D for Vaccines and Therapeutics . Promoting a healthier world! #IndiaForTheWorld

#WorldHepatitisDay

Happy Independence Day! May our nation always prosper and shine bright. #NationFirstAlwaysFirst #HappyIndependenceDay

Humbled to host Ambassador Sergio Gor Eric Garcetti & Assistant Secretary Loyce Pace Loyce Pace at our R&D center. Sharing our journey in developing the #dengue vaccine and clinical plans was truly enriching. Heartfelt gratitude to NIH NIAID News for their steadfast partnership in advancing global health

Panacea Biotec welcomes Dr. Rajiv Bahl from ICMR during his visit to our R&D facility. Our meeting revolved around the collaborative Phase III clinical trial discussions for DengiAll, an innovative tetravalent dengue vaccine, in partnership with NIH and NIAID News.

#HappyChilRunDay

#HealthForAll ICMR and Panacea Biotec initiate the First Dengue Vaccine Phase 3 Clinical Trial in India with Indigenous #Dengue Vaccine, DengiAll The initiation of this Phase 3 clinical trial for India's first indigenous dengue vaccine marks a critical advancement in our

Panacea Biotec and DFC Invests are excited to share that DFC has committed $20 million as a long-term loan for scale-up of Panacea Biotec's EasySix® vaccine - the world's first fully-liquid wP-IPV containing Hexavalent vaccine. Rajesh Jain

1/4. A phase III study of a novel tetravalent vaccine (#DengiAll) manufactured by Panacea Biotec, New Delhi has begun at the ICMR-Rajendra Memorial Research Institute of Medical Sciences (#RMRIMS) in Patna.

Welcoming everyone to the Inaugural Session of the 6th CII Pharma & Life Sciences Summit tomorrow. Register today! cam.mycii.in/ORNew/Registra… #biotech #pharma #HealthcareInnovation #biologics #biosimilars #Vaccine #preventivehealth #CII4INDIA #CII4HEALTH

India’s biotech industry is at a pivotal moment producing 60% of the world’s vaccines, impacting 60-65 million children globally, and on track to become a $300 billion sector. Stronger collaboration between the government and industry is essential, along with harnessing Big Data

Research on Dengue Vaccine Started at JNMC AMU #dengue #ICMR #DengiALL #vaccineawareness 👉amu.ac.in/news/2024/10/1… ICMR National Institute of Epidemiology ICMR Dharmendra Pradhan Jagat Prakash Nadda PMO India Ministry of Health Ministry of Education UGC INDIA ANI Digital ANI Press Trust of India Panacea Biotec ICMR-RMRIMS Rajesh Jain 👇

.Panacea Biotec is expanding its hexavalent vaccine production with a $20M investment from DFC. This single-shot solution provides six immunizations at once, reducing the cost and logistical challenges of delivering vaccines in developing countries. dfc.gov/investment-sto…

This evening, Min. Dr Sabin Nsanzimana and Min. of State Yvan Butera met with Panacea Biotec and @KenupFoundation, to discuss potential collaboration in vaccine manufacturing.

This afternoon, Prime Minister Dr. Ngirente met with Dr. Rajesh Jain, Chairman and Managing Director of Panacea Biotec, an Indian biotechnology firm, during his working visit to Rwanda with his delegation.

Exciting progress! DBT-THSTI, CEPI & Panacea Biotec met at DBT-THSTI on 21.01.25 and discussed strategies to advance the promising betacoronavirus vaccine candidate based on preclinical studies. #vaccines #innovation Department of Biotechnology Rajesh Gokhale G Karthikeyan

For innovation, especially in drug discovery, drug delivery, gene and cell therapy it’s important for the Government to move to the next level and come out with more research linked incentive skills like they did for PLI for the manufacturing sector. - Dr Rajesh Jain, Chairman,